Targeted Sequencing and Resequencing

Global Targeted Sequencing and Resequencing Market to Reach US$22.8 Billion by 2030

The global market for Targeted Sequencing and Resequencing estimated at US$7.4 Billion in the year 2024, is expected to reach US$22.8 Billion by 2030, growing at a CAGR of 20.6% over the analysis period 2024-2030. Sequencing, one of the segments analyzed in the report, is expected to record a 22.8% CAGR and reach US$15.8 Billion by the end of the analysis period. Growth in the Re-Sequencing segment is estimated at 16.6% CAGR over the analysis period.

The U.S. Market is Estimated at US$2.0 Billion While China is Forecast to Grow at 28.0% CAGR

The Targeted Sequencing and Resequencing market in the U.S. is estimated at US$2.0 Billion in the year 2024. China, the world`s second largest economy, is forecast to reach a projected market size of US$5.5 Billion by the year 2030 trailing a CAGR of 28.0% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 16.2% and 18.6% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 17.3% CAGR.

Global Targeted Sequencing and Resequencing Market – Key Trends & Drivers Summarized

Why Are Researchers and Clinicians Prioritizing Targeted Sequencing Over Broader Genomic Approaches?

Targeted sequencing and resequencing are gaining widespread adoption as powerful alternatives to whole-genome and transcriptome sequencing due to their ability to focus on specific genomic regions of interest with exceptional accuracy, efficiency, and cost-effectiveness. Unlike whole-genome approaches, which require significant data processing, storage, and interpretation of vast amounts of non-essential information, targeted sequencing enables scientists to zero in on known disease-associated genes, hotspots, or mutations—yielding clinically actionable results faster and with less computational burden. This precision-driven strategy is especially valuable in diagnostics, where time-sensitive and cost-sensitive tests are needed to inform therapeutic decision-making, such as in oncology, rare disease screening, and pharmacogenomics. Targeted resequencing, in particular, plays a vital role in studying genomic variability among individuals or populations by focusing on previously identified loci, making it an essential tool for population genetics, evolutionary biology, and mutational studies. These approaches also offer deep coverage of selected regions, enabling the detection of low-frequency variants that might be missed with broader sequencing. The flexibility to customize gene panels, the compatibility with degraded samples such as FFPE tissues, and the streamlined data interpretation workflows are further contributing to the increasing reliance on targeted strategies. As the healthcare sector moves toward personalized and precision medicine models, targeted sequencing and resequencing are providing the granularity, scalability, and relevance that researchers and clinicians need to drive impactful discoveries and informed clinical decisions.

How Are Advancements in Technology Enhancing the Capabilities of Targeted Sequencing?

The rapid evolution of sequencing technologies, library preparation kits, and bioinformatics pipelines is significantly enhancing the accuracy, speed, and flexibility of targeted sequencing and resequencing workflows. Next-generation sequencing (NGS) platforms now offer ultra-deep sequencing capabilities with higher throughput, lower error rates, and shorter run times, allowing researchers to interrogate specific genomic regions at single-nucleotide resolution. Hybrid capture and amplicon-based enrichment techniques are becoming more refined, offering high specificity and minimal off-target noise, even in low-input or damaged samples. Improvements in probe design, indexing, and barcoding are enabling the multiplexing of hundreds of samples in a single run without compromising data quality. Emerging long-read technologies are complementing short-read methods, allowing for better resolution of structural variants, repeat regions, and complex genomic rearrangements in targeted regions. Automated workflows and liquid-handling robotics are improving reproducibility and minimizing human error, which is particularly valuable in clinical and high-throughput research labs. On the data analysis side, machine learning algorithms and AI-powered annotation platforms are transforming variant calling, interpretation, and visualization—making it easier to identify clinically relevant mutations and prioritize actionable results. Cloud-based storage and analysis solutions are also becoming more integrated, enabling real-time collaboration, regulatory compliance, and efficient data sharing across research institutions. Additionally, targeted panels are being tailored for specific disease applications, including oncology, cardiogenetics, neurogenetics, and infectious diseases, providing fit-for-purpose diagnostic and research tools. These technological strides are expanding the versatility of targeted sequencing, ensuring it remains a foundational technique in both research and clinical genomics.

Where Is Targeted Sequencing and Resequencing Being Applied, and How Are Use Cases Evolving?

The applications of targeted sequencing and resequencing span a growing array of disciplines, from clinical diagnostics and pharmacogenomics to agricultural genomics and evolutionary biology. In healthcare, targeted sequencing panels are being widely used in oncology to identify driver mutations, guide targeted therapies, and monitor treatment resistance. Liquid biopsy-based tests using targeted panels are gaining traction for non-invasive cancer monitoring and minimal residual disease detection. In rare disease diagnosis, especially for genetically heterogeneous conditions, targeted resequencing enables clinicians to focus on curated sets of genes to improve diagnostic yield while keeping costs manageable. Infectious disease specialists use targeted sequencing to monitor pathogen evolution, resistance gene spread, and outbreak tracking. In pharmacogenomics, panels targeting drug metabolism genes are used to predict patient responses and personalize therapy plans. Beyond human health, plant and animal breeders use targeted sequencing to identify and track desirable traits, support marker-assisted selection, and protect biodiversity. In microbial ecology, researchers use targeted resequencing of specific 16S, 18S, or ITS regions to profile complex communities and study microbial interactions. Population geneticists use targeted resequencing to study ancestral lineages, disease predisposition, and gene-environment interactions across different cohorts. The utility of targeted approaches is also expanding in forensics, where customized panels are used for identity verification, kinship analysis, and mixture resolution. As regulatory standards evolve and NGS becomes more embedded in routine practice, targeted sequencing and resequencing are becoming go-to solutions for laboratories and organizations aiming to maximize scientific yield while minimizing costs and complexity.

What’s Fueling the Global Growth of the Targeted Sequencing and Resequencing Market?

The global market for targeted sequencing and resequencing is being propelled by a combination of rising demand for precision medicine, improvements in sequencing technology, the growing burden of chronic and genetic diseases, and the need for cost-effective genomic solutions. Healthcare systems worldwide are prioritizing rapid, accurate, and clinically relevant diagnostics, which targeted panels are uniquely positioned to deliver. The rising incidence of cancer, rare disorders, and infectious disease outbreaks is pushing demand for fast, high-confidence testing that can guide treatment and containment strategies. Regulatory approvals of panel-based diagnostics and increasing reimbursement support are encouraging clinical adoption across major markets. In the research sector, expanding government and private investment in genomics is supporting the use of targeted methods for high-impact projects, such as biobanking, large cohort studies, and precision agriculture initiatives. The emergence of turnkey sequencing solutions—complete with pre-validated panels, automated prep kits, and integrated analysis software—is lowering the barrier to entry for smaller labs and decentralized facilities. Academic-industrial partnerships are accelerating innovation in disease-specific panel development, ensuring a steady pipeline of relevant solutions tailored to emerging clinical and research needs. Additionally, as global emphasis on data security and compliance grows, cloud-based platforms and secure data pipelines are making it easier to deploy targeted sequencing in regulated environments. The scalability, affordability, and growing range of applications for targeted sequencing and resequencing ensure that this market will continue expanding rapidly—anchored in its ability to deliver focused, high-value genomic insights across disciplines.

SCOPE OF STUDY:

The report analyzes the Targeted Sequencing and Resequencing market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:
Technology (Sequencing, Re-Sequencing); Type (DNA-based targeted sequencing, RNA-based targeted sequencing); Application (Clinical application, Plant & animal sciences, Drug development, Others); End-Use (Hospitals & Clinics, Academic research, Others)

Geographic Regions/Countries:
World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 42 Featured) -

• Agilent Technologies, Inc.
• Azenta Life Sciences (GENEWIZ)
• BGI Genomics
• Bio-Rad Laboratories, Inc.
• CD Genomics
• CosmosID
• DNASTAR, Inc.
• Element Biosciences
• Eurofins Genomics
• F. Hoffmann-La Roche Ltd
• GATC Biotech AG
• Genomatix GmbH
• Illumina, Inc.
• Integrated DNA Technologies, Inc.
• Macrogen, Inc.
• New England Biolabs
• Novogene Corporation
• Oxford Nanopore Technologies plc
• Pacific Biosciences of California, Inc.
• Paragon Genomics
• PerkinElmer, Inc.
• PierianDx

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by artificially increasing the COGS, reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

We are diligently following expert opinions of leading Chief Economists (14,949), Think Tanks (62), Trade & Industry bodies (171) worldwide, as they assess impact and address new market realities for their ecosystems. Experts and economists from every major country are tracked for their opinions on tariffs and how they will impact their countries.

We expect this chaos to play out over the next 2-3 months and a new world order is established with more clarity. We are tracking these developments on a real time basis.

As we release this report, U.S. Trade Representatives are pushing their counterparts in 183 countries for an early closure to bilateral tariff negotiations. Most of the major trading partners also have initiated trade agreements with other key trading nations, outside of those in the works with the United States. We are tracking such secondary fallouts as supply chains shift.

To our valued clients, we say, we have your back. We will present a simplified market reassessment by incorporating these changes!

APRIL 2025: NEGOTIATION PHASE

Our April release addresses the impact of tariffs on the overall global market and presents market adjustments by geography. Our trajectories are based on historic data and evolving market impacting factors.

JULY 2025 FINAL TARIFF RESET

Complimentary Update: Our clients will also receive a complimentary update in July after a final reset is announced between nations. The final updated version incorporates clearly defined Tariff Impact Analyses.

Reciprocal and Bilateral Trade & Tariff Impact Analyses:

USA
CHINA
MEXICO
CANADA
EU
JAPAN
INDIA
176 OTHER COUNTRIES.

Leading Economists - Our knowledge base tracks 14,949 economists including a select group of most influential Chief Economists of nations, think tanks, trade and industry bodies, big enterprises, and domain experts who are sharing views on the fallout of this unprecedented paradigm shift in the global econometric landscape. Most of our 16,491+ reports have incorporated this two-stage release schedule based on milestones.

Please note: Reports are sold as single-site single-user licenses. Electronic versions require 24-48 hours as each copy is customized to the client with digital controls and custom watermarks. The Publisher uses digital controls protecting against copying and printing is restricted to one full copy to be used at the same location.

The latest version of Adobe Acrobat Reader is required to view the report. Upon ordering an electronic version, the Publisher will provide a link to download the purchased report.

Prior to fulfillment of an order, the client will be required to sign a document detailing the purchase terms for a publication from this publisher.